Alligator’s history in immuno-oncology
In July 2026, Alligator discontinued independent drug development to concentrate on its financial interest in HLX22, an anti-HER2 antibody in global Phase 3 that is developed, funded and to be commercialised by Shanghai Henlius Biotech, Inc. This page summarises the research and development Alligator carried out before that decision. The information is kept for reference and is no longer updated.
Alligator today
Alligator is listed on Nasdaq Stockholm (ATORX). The company is entitled to 35% of AbClon’s revenues from Henlius relating to HLX22, including milestones and royalties, equivalent to an effective royalty of up to 1.75% of HLX22 net sales. Alligator neither conducts nor controls the HLX22 programme.
Our research
For more than two decades, Alligator developed antibody-based immunotherapies for cancer from its base in Lund. The work centred on tumour-directed immunotherapy, in particular agonistic antibodies targeting the CD40 and 4-1BB receptors, and on proprietary technologies for antibody discovery and bispecific antibody formats.
Former programmes and their status
Former programmes
- Mitazalimab, a CD40 agonist antibody evaluated in the Phase 2 study OPTIMIZE-1 in first-line metastatic pancreatic cancer. Independent development was discontinued in July 2026. The asset is offered for out-licensing or divestment.
- ATOR-4066, a CD40 × CEACAM5 bispecific antibody based on the Neo-X-Prime® technology. No further development is funded by Alligator.
- ALG.APV-527, a 4-1BB × 5T4 bispecific antibody co-developed with Aptevo Therapeutics and evaluated in a Phase 1 study in solid tumours. No further development is funded by Alligator.
- ATOR-1017 (evunzekibart), a 4-1BB agonist antibody evaluated in a Phase 1 study.
- Antibody technologies: the ALLIGATOR-GOLD® antibody library, the FIND® optimisation technology, and the RUBY™ and Neo-X-Prime® bispecific formats, available for licensing or divestment alongside the related programmes.
Scientific publications
A list of scientific publications and conference presentations from Alligator’s research is kept below for reference.
Presentations
For publications, click here.
- 2025-09-12
ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEACAM5, induces myeloid and T cell dependent tumor immunity and synergizes with PD-1 blockade
Hampus Andersson, Ida Uddbäck, Tova Hermodsson, Mona Celander, Amulya Krishna Shetty, Lill Ljung, Anneli Nilsson, Anette Sundstedt, Laura von Schantz, Laura Varas, Mattias Levin, Anna Säll, Dietmar Wielguny, Kim Jansson, Sara Fritzell, Karin Hägerbrand, Malin Lindstedt and Peter Ellmark. Poster session at CICON25, Utrecht, 10-12 September 2025. - 2025-07-03
CD40 agonist mitazalimab + mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) 24-month follow up and dose characterization from the OPTIMIZE-1 study
Aurelien Lambert, Teresa Macarulla, Ivan Borbath, Karin Geboes, Philippe Cassier, Hans Prenen, Emmanuel Mitry, Inmaculada Gallego Jimenez, Roberto A. Pazo Cid, Jean-Frederic Blanc, Lorenzo Pilla, Mercedes Rodriguez-Garrote, Jaime Feliu, Karin Enell Smith, Sumeet Ambarkhane, Karin Nordbladh, Peter Ellmark, Yago Pico de Coaña and Jean-Luc Van Laethem. Poster session at ESMO GI 2025, Barcelona, 2-5 July 2025. - 2025-06-02
Biomarkers associated with outcomes from OPTIMIZE-1: CD40 agonist mitazalimab with mFOLFIRINOX in patients with untreated metastatic pancreatic cancer
Philippe Alexandre Cassier, Jean-Luc Van Laethem, Ivan Borbath, Teresa Macarulla, Karen Paula Geboes, Aurélien Lambert, Hans Prenen, Emmanuel Mitry, Jean-Frédéric Blanc, Jaime Feliú, Roberto A. Pazo Cid, Inmaculada Gallego Jiménez, Karin Enell Smith, Karin Nordbladh, David Gomez Jimenez, Eileen M. O’Reilly, Yago Pico de Coaña, Sumeet Vijay Ambarkhane, Peter Ellmark, Gregory Lawrence Beatty and OPTIMIZE-1 investigators. Poster session at ASCO Annual Meeting 2025, Chicago, 30 May – 3 June 2025. - 2025-01-24
Evaluating the relative treatment efficacy of CD40 agonist mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) using unanchored indirect treatment comparisons (ITCs)
Eileen M. O’Reilly, Teresa Macarulla, Laetitia Dahan, Ivan Borbath, Philippe Alexandre Cassier, Florent Guelfucci, Armel Ngami, Yago Pico de Coaña, Zev A. Wainberg, Sumeet Vijay Ambarkhane and Jean-Luc Van Laethem. Poster session at ASCO GI 2025, San Francisco, January 23-25, 2025. - 2024-11-09
CD40 agonist mitazalimab combined with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated efficacy and correlative biomarkers from the OPTIMIZE-1 trial
Karen P Geboes, Gregory Beatty, Ivan Borbath, Teresa Macarulla, Aurelien Lambert, Philippe Cassier, Hans Prenen, Emmanuel Mitry, Jean-Frederic Blanc, Lorenzo Pilla, Jaime Feliú, Mercedes Rodriguez-Garrote, Roberto Pazo Cid, Inmaculada Gallego Jimenez, Karin Enell Smith, Karin Nordbladh, David Gomez Jimenez, Peter Ellmark, Yago Pico de Coaña, Sumeet V Ambarkhane, Eileen M O’Reilly and Jean-Luc Van Laethem. Poster session at SITC 2024, Houston, November 6-10, 2024. - 2024-11-09
ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEACAM5, induces myeloid and T-cell dependent anti-tumor activity and synergizes with PD-1 inhibition
Ida Uddbäck, Hampus Andersson, Lill Ljung, Anneli Nilsson, Mona Celander, Amulya Krishna Shetty, David Gomez Jimenez, Malin Lindstedt, Karin Hägerbrand, Sara Fritzell and Peter Ellmark. Poster session at SITC 2024, Houston, November 6-10, 2024 - 2024-11-08
Preliminary results from a phase I dose escalation study of ALG.APV-527, a 5T4 x 4-1BB bispecific antibody, in patients with advanced solid tumors demonstrate favorable safety and biological activity
Thomas Marron, Seth Rosen, Douglas Orr, John Powderly II, Jennifer Segar, Noor Khaskhely, Lynn Bonham, Michelle Nelson, Caroline Taromino,
Daphne Taylor, John Kumer, Ashley Milton, Peter Ellmark, Sara Fritzell, Sumeet Ambarkhane, Dirk Huebner, Asrar Alahmadi. Poster session at SITC 2024, Houston, November 6-10, 2024 - 2024-09-14
First-in-Human Phase I Dose Escalation Study of ALG.APV-527, a 5T4 Tumor Antigen-Conditional 4-1BB Bispecific Antibody, in Patients with Advanced Solid Tumors, Demonstrates Positive Safety, Signals of Biological Activity and Patients with Lasting Stable Disease
Thomas Marron, Seth Rosen, Douglas Orr, John Powderly II, Jennifer Segar, Noor Khaskhely, Lynn Bonham, Michelle Nelson, Caroline Taromino, Daphne Taylor, John Kumer, Peter Ellmark, Sara Fritzell, Sumeet Ambarkhane, Dirk Huebner, Asrar Alahmadi. Poster session at ESMO Congress 2024, Barcelona, September 13-17, 2024 - 2024-06-01
OPTIMIZE-1 primary analysis: Safety, efficacy and biomarker results of a phase 1b/2 study combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)
Jean-Luc Van Laethem, Ivan Borbath, Karen Paula Geboes, Philippe Alexandre Cassier, Aurélien Lambert, Emmanuel Mitry, Hans Prenen, Lorenzo Pilla, Jean-Frédéric Blanc, Inmaculada Gallego Jiménez, Roberto A. Pazo Cid, Mercedes Rodríguez Garrote, Jaime Feliú, Karin Nordbladh, Karin Enell Smith, David Gomez Jimenez, Peter Ellmark, Yago Pico de Coaña, Sumeet Vijay Ambarkhane and Teresa Macarulla. Poster session at ASCO Annual Meeting 2024, Chicago, May 30 – June 3, 2024 - 2024-06-01
CD4 effector T cell expansion identifies objective responses to the CD40 agonist mitazalimab in combination with modified FOLFIRINOX
as first-line therapy for metastatic pancreatic ductal adenocarcinoma in the OPTIMIZE-1 study
Max M. Wattenberg, Karin Enell Smith, Yago Pico de Coaña, David Gomez Jimenez, Sumeet Vijay Ambarkhane, Peter Ellmark and Gregory L. Beatty. Postersession at ASCO Annual Meeting 2024, Chicago, May 30 – June 3, 2024 - 2024-04-09
ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, induces tumor localized immune cell activation in preclinical in vivo tumor model
Hampus Andersson, Ida Uddbäck, Mona Celander, Maria Johansson, Lill Ljung, Anneli Nilsson, Amulya Krishna Shetty, David Gomez Jimenez, Mattias Levin, Sara Fritzell, Laura von Schantz, Malin Lindstedt, Karin Hägerbrand, Anette Sundstedt and Peter Ellmark. Poster Session at AACR Annual Meeting 2024, San Diego, April 5-10, 2024 - 2024-04-08
Mitazalimab, a potent CD40 agonist in combination with FOLFIRINOX demonstrates changes consistent with increased immune activation in TME and peripheral blood in a preclinical pancreatic cancer tumor model
David Gomez Jimenez, Mia Thagesson, Anneli Nilsson, Yago Pico de Coaña, Sumeet Ambarkhane, Karin Enell Smith and Peter Ellmark. Poster Session at AACR Annual Meeting 2024, San Diego, April 5-10, 2024 - 2023-11-03
Combination treatment with ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, and anti-PD-1 reverses T cell exhaustion in vitro
Ida Uddbäck, Sara Fritzell, Lill Ljung, Anneli Nilsson, Mona Celander, Amulya Krishna Shetty, Maria Johansson, Hampus Andersson, David Gomez Jimenez, Mattias Levin, Malin Lindstedt, Karin Hägerbrand, Anette Sundstedt and Peter Ellmark. Poster Session at SITC Annual Meeting 2023, San Diego, November 1-5, 2023 - 2023-09-29
Interim pharmacodynamic analyses of mitazalimab in combination with mFOLFIRINOX in first-line mPDAC identify CD4 effector T cells as a correlate of treatment outcomes
Max M. Wattenberg, Karin Enell Smith, Yago Pico de Coaña, David Gomez Jimenez, Malin Carlsson, Sumeet Vijay Ambarkhane, Peter Ellmark, and Gregory L. Beatty. Poster Session C at AACR Special Conference in Cancer Research: Pancreatic Cancer, Boston, September 27-30, 2023 - 2023-09-28
CD40 agonist mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma Interim efficacy results of the OPTIMIZE-1 phase 1b/2 study
JL Van Laethem, I Borbath, H Prenen, KP Geboes, A Lambert, E Mitry, PA Cassier, JF Blanc, L Pilla, J Feliu, M Rodriguez Garrote, RA Pazo Cid, I Gallego, K Nordbladh, P Ellmark, M Carlsson, Y Pico de Coaña, SV Ambarkhane, and Teresa Macarulla. Plenary Session 3: Clinical Updates at AACR Special Conference in Cancer Research: Pancreatic Cancer, Boston, September 27-30, 2023 - 2023-09-21
Efficacy and pharmacodynamic biomarkers of mitazalimab in combination with chemotherapy in preclinical mouse models
David Gomez Jimenez, Hampus Andersson, Aastha Sobti, Mia Thagesson, Anneli Nilsson, Malin Lindstedt, Karin Hägerbrand, Karin Enell Smith, and Peter Ellmark. Poster #228 CICON 2023, September 20-23, 2023 - 2023-06-05
Efficacy and Safety of mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): an interim analysis of the OPTIMIZE-1 phase 1b/2 study
Hans Prenen, Ivan Borbath, Karen Paula Geboes, Philippe Alexandre Cassier, Aurélien Lambert, Emmanuel Mitry, Teresa Macarulla, Julien Taieb, Jean-Frédéric Blanc, Jaime Feliu Batlle, Mercedes Rodríguez Garrote, Roberto A. Pazo Cid, Manuel Valladares-Ayerbes, Karin Nordbladh, Karin Enell Smith, Peter Ellmark, Malin Carlsson, Yago Pico de Coaña, Sumeet Vijay Ambarkhane, and Jean-Luc Van Laethem, Poster #4139 ASCO Annual Meeting 2023, June 2-6, 2023 - 2023-04-17
ATOR-4066, a Neo-X-PrimeTM bispecific antibody targeting CD40 and CEA, activates myeloid cells in primary human tumors in vitro and induces anti-tumor immunity in vivo
Karin Hägerbrand, Anette Sundstedt, Mattias Levin, Laura Varas, Yago Pico de Coaña, Deniz Bölükbas, Lill Ljung, Maria Johansson, Anneli Nilsson, Mona Celander, Hampus Andersson, David Gomez Jimenez, Malin Lindstedt, and Peter Ellmark, Poster #2939 AACR Annual Meeting 2023, April 14-19, 2023 - 2022-11-10
ATOR-1017, a 4-1BB antibody, demonstrates promising safety and proof of mechanism in a first-in-human study in patients with advanced solid malignancies
Ana Carneiro, Gustav J. Ullenhag, Karin Enell Smith, Lena Schultz, Tova Landström, Peter Ellmark, Malin Carlsson, Sumeet V. Ambarkhane, and Jeffrey Yachnin, Poster #714 SITC Annual Meeting 2022, November 8-12, 2022 - 2022-11-10
Early pharmacodynamic changes measured by RNA sequencing in peripheral blood from patients in a phase 1 study with mitazalimab, a potent CD40 agonistic IgG1 monoclonal antibody
Malin Lindstedt, Aastha Sobti, Sumeet Ambarkhane, Yago Pico de Coaña, Karin Enell Smith, and Peter Ellmark, Poster #35, SITC Annual Meeting 2022, November 8-12, 2022 - 2022-09-13
Mitazalimab (CD40 agonist) in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC); Safety data and recommended dose of phase 2 (RP2D) from OPTIMIZE-1, a phase 1b/2 study
Jean-Luc van Laethem, Ivan Borbath, Hans Prenen, Aurélien Lambert, Karen Geboes, Jean-Frédéric Blanc, Yago Pico de Coaña, Karin Enell Smith, Lena Schultz, Karin Nordbladh, Peter Ellmark, Sumeet Ambarkhane, Malin Carlsson, and Philippe Cassier, Poster AACR Special Conference: Pancreatic Cancer, September 13-16, 2022 - 2022-06-03
Initial findings from a first-in-human, multicenter, open-label study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies
Gustav J. Ullenhag, Ana Carneiro, Karin Enell Smith, Lena Schultz, Sumeet Ambarkhane, Tova Landström, and Jeffrey Yachnin, Poster ASCO, June 3-7, 2022 - 2022-04-13
Mitazalimab, a potent CD40 agonist in combination with chemotherapy redirects and activates tumor infiltrating myeloid cells
Karin Enell Smith, Mia Thagesson, Anneli Nilsson, Doreen Werchau, and Peter Ellmark, Poster AACR, April 13, 2022 - 2021-11-12
ATOR-1017, a second generation 4-1BB antibody with potential to enhance efficacy of PD-1 therapies
Karin Enell Smith, Anneli Nilsson, and Peter Ellmark, Poster SITC, November 12, 2021 - 2021-11-12
Neo-X-Prime™ bispecific antibodies targeting CD40 and tumor antigens promote cross-presentation of tumor exosome-derived neoantigens and induce a superior anti-tumor response
Karin Hägerbrand, Laura Varas, Mattias Levin, Laura von Schantz, Anna Säll, Adnan Deronic, Anette Sundstedt, Lill Ljung, Karin Barchan, Doreen Werchau, Anna Rosén, Maria Johansson, Barnabas Nyesiga, Eva Lindqvist, Mia Thagesson and Peter Ellmark, Poster SITC, November 12, 2021 - 2021-11-12
OPTIMIZE-1, an open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma
Yago Pico de Coaña, Karin Enell Smith, Anette Fält, Maria Flärdh, Peter Ellmark, Philippe Cassier, Jean-Luc van Laethem and Malin Carlsson, Poster SITC, November 12, 2021 - 2021-11-12
ALG.APV-527: A 5T4 tumor directed bispecific approach utilizing ADAPTIRTM technology designed for conditional 4-1BB T cell/NK agonism against solid tumors
Michelle H. Nelson, Anette Sundstedt, Yago Pico de Coaña, Ashly Lucas, Anneli Nilsson, Lill Ljung, Allison Chunyk, Lena Schultz, Catherine McMahan, Jane Gross, Sara Frizell, Hilario Ramos and Peter Ellmark, Poster SITC, November 12, 2021 - 2021-06-07
A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies
Gustav J. Ullenhag, Jeffrey Yachnin, Ana Carneiro, Lena Schultz, Peter Ellmark, Karin Enell Smith, Tina Hjorth, Tova Landström, Poster ASCO, June 7, 2021 - 2021-04-10
Mitazalimab, a potent CD40 agonist with potential for combination with chemotherapy
Adnan Deronic, Mia Thagesson, Anneli Nilsson, Peter Ellmark, Anette Fält, Charlotte Russell and Karin Enell Smith, Poster AACR, April 10, 2021 - 2020-11-09
A bispecific antibody targeting CD40 and EpCAM induces superior anti-tumor effects compared to the combination of monospecific antibodies
Karin Hägerbrand, Mattias Levin, Laura von Schantz, Adnan Deronic, Laura Varas, Anna Säll, Karin Barchan, Doreen Werchau, Lill Ljung, Mia Thagesson, Anna Rosén, Christina Sakellariou, Malin Lindstedt and Peter Ellmark, Poster SITC November 9, 20209 - 2020-11-09
Potent Tumor-Directed T-cell Activation and Tumor Inhibition Induced by a 4-1BB x 5T4 ADAPTIR™ Bispecific Antibody
Michelle Nelson, Robert Miller, Anneli Nilsson, Lill Ljung, Allison Chunyk, Catherine McMahan, David Bienvenue, Maria Askmyr, Gabriela Hernandez-Hoyos and Sara Fritzell, Poster SITC November 9, 2020 - 2020-11-09
Safety and pharmacodynamic activity of ATOR-1015, a CTLA-4 x OX40 bispecific antibody, in a phase 1 dose escalation study of patients with advanced solid malignancies
Jeffrey Yachnin, Gustav J. Ullenhag, Ana Carneiro, Dorte Nielsen, Kristoffer Staal Rohrberg, Anne Månsson Kvarnhammar, Lena Schultz, Erika Bågeman, Camilla Wennersten and Charlotte Astrid Russell, Poster SITC November 9, 2020 - 2020-11-05
Mitazalimab – a CD40 agonist to unleash CD40 in immuno-oncology
Peter Ellmark, PhD, Ass. Prof, VP Discovery Alligator Bioscience, World Immunotherapy Congress, November 5, 2020 - 2020-05-20
A first-in-human phase 1 study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody
Jeffrey Yachnin , Gustav J. Ullenhag , Ana Carneiro , Dorte Nielsen , Kristoffer Staal Rohrberg, Anne Månsson Kvarnhammar, Lena Schultz, Erika Bågeman, Camilla Wennersten, Charlotte Astrid Russell, Poster ASCO May 20, 2020 - 2020-04-27
A first-in-human phase 1 study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody
Jeffrey Yachnin, Gustav J. Ullenhag, Ana Carneiro, Dorte L. Nielsen, Kristoffer Staal Rohrberg, Anne Månsson Kvarnhammar, Erika Bågeman, Camilla S. Wennersten, Charlotte Astrid Russell, Video presentation (in english) April 27, 2020 at AACR Virtual Annual Meeting. - 2019-11-09
ATOR-1017, a 4-1BB Antibody Developed for Tumor-Directed Immunotherapy of Cancer
D Werchau, A Rosén, M Eriksson, S Järnum, C Furebring and K Enell Smith, Poster SITC November 9, 2019 - 2019-11-09
Potent Tumor-Directed T cell Activation and Tumor Inhibition Induced by a 4-1BB x 5T4 ADAPTIR™ Bispecific Antibody
M Nelson, R Miller, R Bader, D Werchau, A Nilsson, L Ljung, A Deronic, A Chunyk, L Schultz, C McMahan, D Bienvenue, A Dahlman, S Fritzell, M Askmyr, G Hernandez-Hoyos, Poster SITC November 9, 2019 - 2019-09-26
4224, a tumor exosome-transforming antibody targeting CD40 and EpCAM, induces superior anti-tumor effects compared to monospecific CD40 antibody
Adnan Deronic, Laura von Schantz, Mia Thagesson, Kristine Smedenfors, Christina Sakellariou, Lill Ljung, Fredrika Carlsson, Doreen Werchau, Malin Lindstedt, Peter Ellmark, Karin Hägerbrand, CICON, 26 september 2019 - 2019-06-01
A first-in-human, multicenter, open-label, phase 1 study in patients with advanced and/or refractory solid malignancies to evaluate the safety of intravenously administered ATOR-1015
Jeffrey Yachnin, Gustav J Ullenhag, Ana Carneiro, Dorte Nielsen, Kristoffer Staal Rohrberg, Anne Månsson Kvarnhammar, Anna Dahlman, Erika Bågeman, Camilla Wennersten , Charlotte Astrid Russell., Poster ASCO 1 juni 2019 - 2019-04-11
RUBYTM – A novel recombinant universal bispecific antibody format for generation of bsAb with outstanding stability, manufacturability and shorter development timelines
A Säll, M Levin, B Nyesiga, M Mårtensson, S Fritzell, K Hägerbrand, C Furebring, L von Schantz, Poster PEGS 11 April 2019 - 2019-04-02
ATOR-1144 is a tumor-directed CTLA-4 x GITR bispecific antibody that acts by depleting Tregs and activating effector T cells and NK cells
S Fritzell, M Levin, A Dahlman, I Åberg, M Johansson, M Winnerstam, K Enell Smith, P Ellmark, C Furebring, P Norlén, A Månsson Kvarnhammar, AACR Annual Meeting April 2, 2019 - 2019-04-01
Preclinical safety and efficacy of a tumor-directed T cell activating 4-1BB x 5T4 ADAPTIR™ bispecific antibody
A Dahlman, M Nelson, J Bannink, Starrla Johnson, D Werchau, A Nilsson, L Ljung, G Blahnik-Fagan, R Bader, P Ellmark, M Askmyr, G Hernandez-Hoyos, C McMahan, S Fritzell, AACR 1 april 2019 - 2018-11-09
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand, Mia Thagesson, Doreen Werchau, Kristine Smedenfors, Anna Dahlman, Anna Rosén, Maria Johansson, Ida Åberg, Per Norlén, Christina Furebring and Peter Ellmark, SITC 9 november 2018 - 2018-11-09
ATOR-1017, a tumor directed Fcγ-receptor cross-linking dependent 4-1BB agonistic antibody
Karin Enell Smith, Anna Rosén, Anna Dahlman, Karin Barchan, Ida Åberg, Doreen Werchau, Mia Thagesson, Niina Veitonmäki, Christina Furebring, Peter Ellmark, SITC 9 november 2018 - 2018-11-09
Potent Tumor-Directed T cell Activation and Tumor Inhibition Induced by a 4-1BB x 5T4 ADAPTIR™ Bispecific Antibody
Michelle Nelson, Gabriele Blahnik-Fagan, Robert Bader, Doreen Werchau, Anneli Nilsson, Lill Ljung, Jeannette Bannink, Danielle Mitchell, Lynda Misher, Catherine McMahan, David Bienvenue, Maria Askmyr, Anna Dahlman, Peter Ellmark, Gabriela Hernandez-Hoyos, Sara Fritzell, SITC 9 november 2018 - 2018-09-30
ATOR-1017; a 4-1BB antibody designed for superior safety/efficacy profile in cancer immunotherapy
Eva Dahlén, Anna Rosén, Adnan Deronic, Karin Barchan, Anna Dahlman, Peter Ellmark, Tina Furebring och Karin Enell Smith., 4th CRI-CIMT-EATI-AACR International Cancer lmmunotherapy Conference 30 september 2018. - 2018-06-23
The agonistic CD40 antibody improves T cell responses and delays growth of a syngeneic tumor in an ovalbumin vaccination model
Adnan Deronic, Anneli Nilsson, Mia Thagesson, Doreen Werchau, Niina Veitonmäki, Per Norlén, Christina Furebring and Peter Ellmark, World Preclinical Congress June 2018 - 2018-05-16
CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand, Mia Thagesson, Doreen Werchau, Kristine Smedenfors, Anna Rosén, Maria Johansson, Per Norlén, Christina Furebring and Peter Ellmark, Poster CIMT 16 May 2018 - 2018-05-16
Tumor Antigen-dependent T Cell Activation And Tumor Localization Induced By A Novel 4-1BB X 5T4 ADAPTIR™ Bispecific Antibody
Sara Fritzell, Doreen Werchau, Maria Askmyr, Niina Veitonmäki, Anneli Nilsson, Adnan Deronic, Mia Thagesson, Anna Säll, Laura von Schantz, Robert Bader, Gabriele Blahnik-Fagan, Michelle Nelson, David Bienvenue, Gabriela Hernandez-Hoyos, Peter Ellmark , Poster CIMT 16 May 2018 - 2018-05-05
Activation of the CD137 Pathway in T cells by a CD137 x 5T4 bispecific ADAPTIR™ Molecule Requires Co-engagement of CD137 and 5T4
Gabriele Blahnik-Fagan, Robert Bader, Jeannette Bannink, Danielle Mitchell, Lynda Misher, Cathy McMahan, David Bienvenue, Laura von Schantz, Eva Lindqvist, Doreen Werchau, Anneli Nilsson, Maria Askmyr, Niina Veitonmäki, Sara Fritzell, Peter Ellmark, Michelle Nelson, and Gabriela Hernandez-Hoyos, Poster AAI 5 May 2018 - 2018-05-02
Design and Generation of Bispecific Antibodies for Immuno-Oncology
von Schantz L, Säll A, Carlsson F, Thorulffsson M, Petersson J, Tsiobanelis K, Nyesiga B, Jansson K, Rosén A, Hägerbrand K, Dahlman A, Månsson-Kvarnhammar A, Veitonmäki N and Furebring C., Poster PEGS 2 May 2018 - 2018-05-02
Screening, Optimization and Characterization of a Novel 4-1BB x 5T4 ADAPTIR™ Bispecific Antibody
von Schantz L, Misher L, Mitchell D, Gruswitz F, Woodruff B, Daugherty M, Aguilar M, Huntington K, Bader R, Blahnik-Fagan G, Säll A, Werchau D, Thagesson M, Nilsson A, Deronic A, Askmyr M, Veitonmäki N, Fritzell S, Ellmark P, Hernandez-Hoyos G and Bienvenue D., Poster PEGS 2 May 2018 - 2018-04-18
CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
Veitonmäki N, Månsson Kvarnhammar A, Fritzell S, Enell Smith K, Thagesson M, Werchau D, Hägerbrand K, Rosén A, Johansson M, Norlén P, Furebring C, Ellmark P, Poster AACR 17 April 2018
Publications
- 2026-04-21
First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies
V. Ekström-Rydén, A. Carneiro, J. Yachnin, K. Staal Rohrberg, K. Enell Smith, P. Ellmark, R. Løvendahl Eefsen and G. J. Ullenhag, ESMO Open, 21 April 2026 - 2025-11-28
REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer
Songul Kucukcelebi, Freek R. van ‘t Land, Sjoerd H. van der Burg, Ferry A. L. M. Eskens, Marjolein Y. V. Homs, Marcella Willemsen, Anne Onrust-van Schoonhoven, Nina E. M. Rozendaal, Amine Fellah, Disha Vadgama, Miranda Moskie, Koen Bezemer, Michail Doukas, Casper W. F. van Eijck, Ralph Stadhouders, Judith de Vos-Geelen, Aniek E. van Diepen, Ilona Enninga, Rob Meijer, Sumeet V. Ambarkhane, Peter Ellmark, Joachim G. J. V. Aerts, Christianne Groeneveldt and Casper H. J. van Eijck, Nature Communications, 28 November 2025 - 2025-10-07
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1
Jean-Luc Van Laethem, Karen Geboes, Ivan Borbath, Teresa Macarulla Mercade, Aurélien Lambert, Philippe Cassier, Hans Prenen, Emmanuel Mitry, Jean-Frédéric Blanc, Lorenzo Pilla, Jaime Feliu, Mercedes Rodriguez Garrote, Roberto Antonio Pazo-Cid, Inmaculada Gallego, Karin Enell Smith, Karin Nordbladh, David Gomez Jimenez, Peter Ellmark, Yago Pico de Coaña, Sumeet Vijay Ambarkhane, Gregory L. Beatty and Eileen M. O’Reilly, Cell Reports Medicine, October 7, 2025 - 2025-09-10
ATOR-4066, a bispecific antibody targeting CD40 and CEACAM5, induces strong myeloid and T cell–dependent tumor immunity and synergizes with PD-1 blockade
Hampus Andersson, Ida Uddbäck, Tova Hermodsson, Mona Celander, Amulya Krishna Shetty, Lill Ljung, Anneli Nilsson, Anette Sundstedt, Laura von Schantz, Laura A. Varas, Mattias Levin, Anna Säll, Dietmar Weilguny, Kim Jansson, Sara Fritzell, Karin Hägerbrand, Malin Lindstedt and Peter Ellmark, Cancer Cell Research, September 10, 2025 - 2025-05-26
Antigenic peptide delivery to antigen-presenting cells using a CD40-coiled coil affinity-based platform
Barnabas Nyesiga, Karin Hägerbrand, Laura Varas, Anette Gjörloff Wingren, Mats Ohlin, Peter Ellmark and Laura von Schantz, Drug Deliv, May 26, 2025 - 2025-01-22
First- in- human, multicenter, open- label, phase I study of ATOR- 1017 (evunzekibart), a 4- 1BB antibody, in patients with advanced solid malignancies
Ana Carneiro, Amanda Hahn, Peter Ellmark , Karin Enell Smith, Lena Schultz, Sumeet Ambarkhane, Jeffrey Yachnin and Gustav J. Ullenhag, J Immunother Cancer, January 22, 2025 - 2024-06-01
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study
Jean-Luc Van Laethem, Ivan Borbath, Hans Prenen, Karen Paula Geboes, Aurélien Lambert, Emmanuel Mitry, Philippe Alexandre Cassier, Jean-Frédéric Blanc, Lorenzo Pilla, Jaime Feliu Batlle, Mercedes Rodriguez Garrote, Roberto Antonio Pazo-Cid, Inmaculada Gallego, Karin Enell Smith, Peter Ellmark, Yago Pico de Coaña, Sumeet Vijay Ambarkhane and Teresa Macarulla, Lancet Oncol. June 1, 2024 - 2024-05-20
Next generation CD40 agonists for cancer immunotherapy
Hampus Andersson, Barnabas Nyesiga, Tova Hermodsson, Karin Enell Smith, Karin Hägerbrand, Malin Lindstedt and Peter Ellmark, Expert Opin Biol Ther. May 20, 2024 - 2024-03-25
RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties
Barnabas Nyesiga, Mattias Levin, Anna Säll, Anna Rosén, Kim Jansson, Sara Fritzell, Karin Hägerbrand, Dietmar Weilguny and Laura von Schantz, mAbs, March 25, 2024 - 2023-10-05
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1
Karin Enell Smith, Sara Fritzell, Anneli Nilsson, Karin Barchan, Anna Rosén, Lena Schultz, Laura Varas, Anna Säll, Nadia Rose, Maria Håkansson, Laura von Schantz and Peter Ellmark, Cancer Immunology, Immunotherapy, October 5, 2023 - 2023-09-27
Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody
Hampus Andersson ,Aastha Sobti, David Gomez Jimenez, Yago Pico de Coaña, Sumeet Vijay Ambarkhane, Karin Hägerbrand, Karin Enell Smith, Malin Lindstedt and Peter Ellmark, Cells, September 27, 2023 - 2022-11-07
The bispecific tumor antigen-conditional 4-1BB x 5T4 agonist, ALG.APV-527, mediates strong T cell activation and potent anti-tumor activity in preclinical studies
Michelle H. Nelson, Sara Fritzell, Robert Miller, Doreen Werchau, Danielle Van Citters, Anneli Nilsson, Lynda Misher, Lill Ljung, Robert Bader, Adnan Deronic, Allison G. Chunyk, Lena Schultz, Laura A. Varas, Nadia Rose, Maria Håkansson, Jane Gross, Christina Furebring, Peter Pavlik, Anette Sundstedt, Niina Veitonmäki, Hilario J. Ramos, Anna Säll, Anna Dahlman, David Bienvenue, Laura von Schantz, Catherine J. McMahan, Maria Askmyr, Gabriela Hernandez Hoyos and Peter Ellmark, Molecular Cancer Therapeutics, November 7, 2022 - 2022-11-02
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
Karin Hägerbrand, Laura Varas, Adnan Deronic, Barnabas Nyesiga, Anette Sundstedt, Lill Ljung, Christina Sakellariou, Doreen Werchau, Mia Thagesson, David Gomez Jimenez, Lennart Greiff, Mona Celander, Kristine Smedenfors, Anna Rosén, Deniz Bölükbas, Fredrika Carlsson, Mattias Levin, Anna Säll, Laura von Schantz, Malin Lindstedt and Peter Ellmark, Journal for ImmunoTherapy of Cancer, November 2, 2022 - 2022-04-10
Kick-starting tumor specific T cell priming & targeting the tumor microenvironment using CD40 targeting bispecific antibodies
Karin Hägerbrand and Peter Ellmark, Immuno-Oncology Insights, April 10, 2022 - 2021-12-15
CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
Itziar Otano, Arantza Azpilikueta, Javier Glez-Vaz, Maite Alvarez, José Medina-Echeverz, Ivan Cortés-Domínguez, Carlos Ortiz-de-Solorzano, Peter Ellmark, Sara Fritzell, Gabriela Hernandez-Hoyos, Michelle Hase Nelson, María Carmen Ochoa, Elixabet Bolaños, Doina Cuculescu, Patricia Jaúregui, Sandra Sanchez-Gregorio, Iñaki Etxeberria, María E. Rodriguez-Ruiz, Miguel F. Sanmamed, Álvaro Teijeira, Pedro Berraondo and Ignacio Melero, Nature Communications, 15 December 2021 - 2021-06-17
Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy
Karin Enell Smith, Adnan Deronic, Karin Hägerbrand, Per Norlén and Peter Ellmark, Expert Opinion on Biological Therapy, June 17, 2021 - 2021-05-05
The human anti‑CD40 agonist antibody mitazalimab (ADC‑1013; JNJ‑64457107) activates antigen‑presenting cells, improves expansion of antigen‑specific T cells, and enhances anti‑tumor efficacy of a model cancer vaccine in vivo
Adnan Deronic, Anneli Nilsson, Mia Thagesson, Doreen Werchau, Karin Enell Smith and Peter Ellmark, Cancer Immunology Immunotherapy, 5 May, 2021 - 2020-03-09
Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy
Maria Georganaki, Mohanraj Ramachandran, Sander Tuit, Nicolás Gonzalo Núñez, Alexandros Karampatzakis,a Grammatiki Fotaki, Luuk van Hooren, Hua Huang, Roberta Lugano, Thomas Ulas, Aura Kaunisto, Eric C Holland, Peter Ellmark, Sara M Mangsbo, Joachim Schultze, Magnus Essand, Sonia Tugues, and Anna Dimberg, Oncoimmunology, 9 March 2020 - 2019-04-11
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand, Anna Dahlman, Karin Enell Smith, Sara Fritzell, Laura von Schantz, Mia Thagesson, Doreen Werchau, Kristine Smedenfors, Maria Johansson, Anna Rosén, Ida Åberg, Magnus Winnerstam, Eva Nyblom, Karin Barchan, Christina Furebring, Per Norlén, Peter Ellmark, Journal for ImmunoTherapy of Cancer, 11 April 2019 - 2019-03-08
First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies
Sandra M M Irenaeus, Dorte Nielsen, Peter Ellmark, Jeffrey Yachnin, Adnan Deronic, Anneli Nilsson, Per Norlén, Niina Veitonmäki, Camilla S Wennersten, Gustav J Ullenhag, International Journal of Cancer, 8 March 2019 - 2018-03-28
Bispecific antibodies in cancer immunotherapy
Eva Dahlén, Niina Veitonmäki and Per Norlén, Therapeutic advances in vaccines and immunotherapy, 28 March 2018 - 2017-09-13
Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression
Jonathan P O Hebb, Adriane R Mosley, Felipe Vences-Catalán, Narendiran Rajasekaran, Anna Rosén, Peter Ellmark and Dean W Felsher, Cancer Immunology, Immunotherapy, 13 September 2017 - 2016-12-13
Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer
Luuk van Hooren, Linda C Sandin, Igor Moskalev, Peter Ellmark, Anna Dimberg, Peter Black, Thomas H Tötterman, and Sara M Mangsbo, European Journal of Immunology, 13 December 2016 - 2016-10-06
Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
Peter Ellmark, Sara M Mangsbo, Christina Furebring, Per Norlén, and Thomas H Tötterman, Cancer Immunology, Immunotherapy, 6 October 2016 - 2016-10-05
Selective FcγR engagement by human agonistic anti-CD40 antibodies
Peter Ellmark, Sara M Mangsbo, and Malin Lindstedt, Translational Cancer Research, 5 October 2016 - 2015-03-16
Kick-starting the cancer-immunity cycle by targeting CD40
Peter Ellmark, Sara M Mangsbo, Christina Furebring, Thomas H Tötterman, and Per Norlén, Oncoimmunology, 16 March 2015 - 2014-10-14
The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity
Sara M Mangsbo, Sissela Broos, Erika Fletcher, Niina Veitonmäki, Christina Furebring, Eva Dahlén, Per Norlén, Malin Lindstedt, Thomas H Tötterman and Peter Ellmark, Clinical Cancer Research, 14 Oct 2014 - 2014-01-16
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo
Linda C Sandin, Fredrik Eriksson, Peter Ellmark, Angelica Si Loskog, Thomas H Tötterman and Sara M Mangsbo, Oncoimmunology, 16 January 2014 - 2013-10-21
Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer
Linda C Sandin, Anna Orlova, Erika Gustafsson, Peter Ellmark, Vladimir Tolmachev, Thomas H Tötterman and Sara M Mangsbo, Cancer Immunology Research, 21 October 2013 - 2012-06-09
Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(γ-glutamic acid) nanoparticles
Sissela Broos, Linda C Sandin, Jenny Apel, Thomas H Tötterman, Takami Akagi, Mitsuru Akashi, Carl A K Borrebaeck, Peter Ellmark and Malin Lindstedt, 9 June 2012
Enquiries
Questions about the company: ir@alligatorbioscience.com, +46 46 540 82 00.
Enquiries about licensing or acquiring mitazalimab or the other assets: bd@alligatorbioscience.com
Disclaimer
The information on this page is historical. It describes activities that have ended, is not updated and may no longer be accurate. It should not be relied on as a basis for any investment decision.
For current information, please refer to Alligator’s most recent financial report and press releases.